Page last updated: 2024-10-22

alendronate and Asthma

alendronate has been researched along with Asthma in 9 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women."6.71Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005)
" Seventy-eight participants with persistent asthma receiving 250 μg of fluticasone twice daily for 2 weeks were randomized to receive alendronate or placebo while initiating salmeterol for 8 weeks."5.30Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. ( Boushey, HA; Cardet, JC; Castro, M; Chinchilli, VM; Codispoti, CD; Dyer, AM; Gerard, N; Holguin, F; Israel, E; Jiang, X; Kraft, M; Lazarus, S; Lemanske, RF; Lu, Q; Lugogo, N; Mauger, D; McIntire, K; Moore, WC; Moy, J; Ortega, VE; Peters, SP; Smith, LJ; Solway, J; Sorkness, CA; Sumino, K; Wechsler, ME; Wenzel, S, 2019)
"A 6-year-old East Indian boy with asthma was mistakenly given alendronate, a bisphosphonate, for 3 months instead of montelukast, a leukotriene-receptor antagonist."3.72Dispensing error leading to alendronate ingestion. ( Bailey, B; Carrière, B; Chabot, G; Lebel, D, 2003)
"We have recently shown that long-term use of inhaled corticosteroids decreases bone mineral density (BMD) of the lumbar spine in postmenopausal asthmatic women."2.71Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. ( Fujita, K; Fujita, M; Goya, K; Kasayama, S; Kawase, I; Miyatake, A; Morimoto, Y; Yamamoto, H, 2005)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's7 (77.78)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cardet, JC1
Jiang, X1
Lu, Q1
Gerard, N1
McIntire, K1
Boushey, HA1
Castro, M1
Chinchilli, VM1
Codispoti, CD1
Dyer, AM1
Holguin, F1
Kraft, M1
Lazarus, S1
Lemanske, RF1
Lugogo, N1
Mauger, D1
Moore, WC1
Moy, J1
Ortega, VE1
Peters, SP1
Smith, LJ1
Solway, J1
Sorkness, CA1
Sumino, K1
Wechsler, ME1
Wenzel, S1
Israel, E1
Pala, G1
Perfetti, L1
Cappelli, I1
Caminati, M1
Moscato, G1
Isik, A1
Uras, I1
Uyar, ME1
Karakurt, F1
Kaftan, O1
Carrière, B1
Bailey, B1
Chabot, G1
Lebel, D1
Kasayama, S1
Fujita, M1
Goya, K1
Yamamoto, H1
Fujita, K1
Morimoto, Y1
Kawase, I1
Miyatake, A1
Smith, BJ1
Laslett, LL1
Pile, KD1
Phillips, PJ1
Phillipov, G1
Evans, SM1
Esterman, AJ1
Berry, JG1
Ornoy, A1
Wajnberg, R1
Diav-Citrin, O1
Goldstein, MF1
Fallon, JJ1
Harning, R1
Lau, EM1
Woo, J1
Chan, YH1
Li, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Proof of Concept Study of Alendronate for Asthma[NCT02230332]Phase 2/Phase 378 participants (Actual)Interventional2015-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Asthma Control Test (ACT)

Asthma Control Test : Score calculated as the sum total of a 5-item questionnaire. Each item ranges from 1 (poor control) to 5 (good control) so that the range of the total score is 5 to 25. Scores below 20 indicate that asthma is not well controlled. (NCT02230332)
Timeframe: 8 weeks after randomization

Interventionunits on a scale (Mean)
Alendronate22.2
Placebo22.2

Beta-2 Adrenergic Receptor Agonist-induced cAMP Production

Peripheral blood mononuclear cells cAMP concentrations measured using isoproterenol (ISO) as a beta-2 adrenergic receptor agonist, and using phosphate buffered saline (PBS) as a positive control. The outcome is expressed as the ratio of cAMP concentration using ISO relative to cAMP concentration using PBS. (NCT02230332)
Timeframe: 8 weeks after randomization

Interventionratio (Geometric Mean)
Alendronate5.9
Placebo5.9

Fractional Exhaled Nitrix Oxide

(NCT02230332)
Timeframe: 8 weeks after randomization

Interventionparts per billion (Geometric Mean)
Alendronate16.8
Placebo15.4

Peripheral Blood Mononuclear Cell ADRB2 Cell Surface Density

(NCT02230332)
Timeframe: 8 weeks after randomization

Interventionnumber of receptors per cell (Geometric Mean)
Alendronate1680
Placebo1863

Salivary Alpha Amylase Ratio (Post-Salmeterol / Pre-Salmeterol)

Salivary Alpha Amylase (sAA) levels from saliva samples obtained through passive drooling, before and 1 hour after Salmeterol administration. The outcome is expressed as the ratio of the Post-Salmeterol to the Pre-Salmeterol sAA levels. (NCT02230332)
Timeframe: 8 weeks after randomization

Interventionratio (Mean)
Alendronate1.6
Placebo1.6

Salmeterol Protected Methacholine Challenge PC20

Following administration of Salmeterol, the concentration of Methacholine required to produce a 20% drop in FEV1 - measured in mg/ml and reported on log base 2 scale. (NCT02230332)
Timeframe: 8 weeks after randomization

Interventionmg/ml on log base 2 scale (Mean)
Alendronate1.8
Placebo1.7

Reviews

1 review available for alendronate and Asthma

ArticleYear
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.
    Chest, 1999, Volume: 116, Issue:6

    Topics: Administration, Inhalation; Administration, Oral; Adult; Alendronate; Asthma; Bone Density; Bone Rem

1999

Trials

4 trials available for alendronate and Asthma

ArticleYear
Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.
    The Journal of allergy and clinical immunology, 2019, Volume: 144, Issue:2

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Alendronate; Asthma; Double-Blind Method

2019
Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids.
    Metabolism: clinical and experimental, 2005, Volume: 54, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Alendronate; Asthma; Bone and Bones; Bone

2005
Randomized controlled trial of alendronate in airways disease and low bone mineral density.
    Chronic respiratory disease, 2004, Volume: 1, Issue:3

    Topics: Absorptiometry, Photon; Aged; Alendronate; Asthma; Bone Density; Bone Density Conservation Agents; F

2004
Alendronate for the prevention of bone loss in patients on inhaled steroid therapy.
    Bone, 2001, Volume: 29, Issue:6

    Topics: Administration, Inhalation; Alendronate; Asthma; Bone Density; Double-Blind Method; Female; Glucocor

2001

Other Studies

4 other studies available for alendronate and Asthma

ArticleYear
Occupational rhinitis to sodium alendronate.
    Allergy, 2008, Volume: 63, Issue:8

    Topics: Adult; Alendronate; Asthma; Female; Humans; Occupational Diseases; Occupational Exposure; Rhinitis

2008
Alendronate-induced asthma.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:3

    Topics: Alendronate; Asthma; Bone Density Conservation Agents; Drug Hypersensitivity; Female; Humans; Middle

2009
Dispensing error leading to alendronate ingestion.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:1

    Topics: Acetates; Alendronate; Asthma; Calcium Channel Blockers; Child; Cyclopropanes; Drug Packaging; Esoph

2003
The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
    Reproductive toxicology (Elmsford, N.Y.), 2006, Volume: 22, Issue:4

    Topics: Adult; Alendronate; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Behcet Syndrome; Berylliosi

2006